NAMS (NAMS) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving NAMS (NAMS) right now is Obicetrapib approval path: Obicetrapib has posted positive pivotal Phase 3 data (LDL-C reductions of roughly 33% as monotherapy and about 49% combined with ezetimibe in reported studies), which underpins regulatory filings in the US and Europe. Revenue (TTM) is ~$22.6M. If that keeps playing out, the setup is favourable; the risk to it is the company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. No one can predict where NAMS trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive NAMS (NAMS) higher?
1. Obicetrapib approval path
Obicetrapib has posted positive pivotal Phase 3 data (LDL-C reductions of roughly 33% as monotherapy and about 49% combined with ezetimibe in reported studies), which underpins regulatory filings in the US and Europe. Approval as an oral, non-statin add-on would open a large addressable population of statin-treated patients who remain above LDL targets.
2. Oral, once-daily convenience versus injectables
The competitive pitch is a pill rather than an injection. Leading potent LDL-lowering drugs such as PCSK9 inhibitors are injectables, so an effective oral option could appeal to patients and prescribers who prefer a tablet, potentially widening use in primary care.
3. Deep cash runway and Menarini partnership
About $707 million in cash and marketable securities (as of Q1 2026) funds the ongoing PREVAIL outcomes trial and launch preparation without immediate financing pressure. The Menarini Group partnership provides ex-US commercialization reach and some non-dilutive economics.
4. Cardiovascular outcomes optionality
The PREVAIL cardiovascular outcomes trial could, if positive, extend the label from LDL lowering to demonstrated event reduction, which historically drives payer coverage and broader adoption. A favorable outcomes readout would be the single largest potential value inflection.
What could weigh on NAMS?
The company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. CETP inhibitors as a class have a difficult history, with several prior candidates from large pharma failing in outcomes trials, which keeps skepticism elevated. Concentration is extreme because essentially all value sits in one molecule. Ongoing losses mean future capital raises and shareholder dilution are possible despite the current cash cushion. Commercial risk is real even after approval, given entrenched generics, injectable PCSK9 competitors, and payer access hurdles.
Where NAMS trades today
A forecast starts from where the stock actually is. These are NAMS's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for NAMS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a NAMS forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the NAMS guide and whether NAMS is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the NAMS outlook
The bottom line: what is driving NAMS (NAMS) is Obicetrapib approval path, with revenue (ttm) at ~$22.6M. If that keeps playing out the setup is favourable; the risk is the company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. No one can predict the price, so treat any NAMS forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around NAMS with Walnut
Use NAMS as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for NAMS (NAMS)?
+
No one can reliably predict where NAMS will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push NAMS higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive NAMS higher?
+
The main growth drivers are Obicetrapib approval path; Oral, once-daily convenience versus injectables; Deep cash runway and Menarini partnership. Whether they play out is the real question, not a guaranteed path.
What are the risks to NAMS?
+
The company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. CETP inhibitors as a class have a difficult history, with several prior candidates from large pharma failing in outcomes trials, which keeps skepticism elevated. Concentration is extreme because essentially all value sits in one molecule. Ongoing losses mean future capital raises and shareholder dilution are possible despite the current cash cushion. Commercial risk is real even after approval, given entrenched generics, injectable PCSK9 competitors, and payer access hurdles.
Will NAMS stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. NAMS's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is NAMS a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the NAMS "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.